In a significant move, health authorities have endorsed the broader therapeutic use of GLP-1 receptor and dual incretin agonists, highlighting their considerable metabolic and cardiovascular benefits while acknowledging ongoing safety concerns. Vigilance is warranted due to rare but serious risks like gastrointestinal upset and emerging issues such as vitreous hemorrhage, particularly in nondiabetic patients. Despite a generally negative social media sentiment surrounding these drugs, patient acceptance remains high, marking a pivotal moment in obesity and diabetes management.
Title not available for this citation.
“This case was also complicated because of the past medical history of autoimmune disorder and granulomatosis polyangiitis, which required additional testing to rule out a possible autoimmune etiology of the current presentation. To our knowledge, this is a rare case of semaglutide-associated SBO and concomitant AKI requiring temporary dialysis, highlighting the adverse effects of GLP-1 receptor agonists and the need for further studies to help formulate best practice guidelines.”
Title not available for this citation.
“Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the treatment of diabetes mellitus and obesity.”
Title not available for this citation.
“Patients on GLP-1RAs had a significantly higher risk of postoperative radiculopathy (p<.001), infection (p=.013), and readmission (p<.001).”
Title not available for this citation.
“Preoperative GLP-1RA use was associated with increased postoperative risk of radiculopathy and decreased rates of pseudoarthrosis.”
Title not available for this citation.
“The incidence of pseudoarthrosis remained significantly reduced in the GLP-1RA cohort (2.7% vs. 5.2%, p=.019).”
Title not available for this citation.
“Tirzepatide is a synthetic polypeptide classified as glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist.”
Title not available for this citation.
“It stimulates insulin secretion from the pancreas and helps lower blood sugar levels in patients with type 2 diabetes mellitus.”
Title not available for this citation.
“We report a case of unilateral vitreous hemorrhage in a middle-aged woman on tirzepatide for weight loss.”
Title not available for this citation.
“Vitreous hemorrhage spontaneously resolved and uncorrected visual acuity improved to 1.0 over a period of four months.”
Title not available for this citation.
“The key point to be conveyed from this case is the need for more studies into whether there is a causal relationship between tirzepatide and vitreous hemorrhage in nondiabetic patients.”
Title not available for this citation.
“Tirzepatide, a novel dual glucagon inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the management of type 2 diabetes mellitus (T2DM) and chronic weight management.”
Title not available for this citation.
“This case report details a 47-year-old male with a history of obesity and T2DM who presented with an ecchymotic, petechial rash within a week of increasing the dose of tirzepatide to 12.5 mg.”
.jpg&width=160)